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Lessons from placebo effects in migraine 
treatment






Abstract In medical research, the
placebo effect is an important
methodological tool. Placebo is
given to participants in clinical 
trials, with the intention of 
mimicking an experimental 
intervention. The “nocebo” effect,
on the other hand, is the phenome-
non whereby a patient who believes
that a treatment will cause harm
actually does experience adverse
effects. The placebo effect strongly
influences the way the results of
clinical trials are interpreted.
Placebo responses vary with the
choice of study design, the choice
of primary outcome measure, the
characteristics of the patients and
the cultural setting in which the
trial is conducted. In migraine 
trials, the placebo response is high,
in terms of both efficacy and side
effects. Although medical ethics
committees are becoming increas-
ingly resistant to the use of placebo
in acute migraine trials, placebo
nevertheless remains the pivotal
comparator in trials of migraine
medications.
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The word “placebo”, which literally means “I shall
please”, derives from the Latin Placebo domino in regione
vivorum (“I shall please the Lord in the land of the liv-
ing”). It was first used in the 14th century in reference to
hired professional mourners at funerals and thus had asso-
ciations with the ideas of depreciation and substitution
[1]. Around the same time, Chaucer in The Canterbury
Tales (The Merchant’s Tale) depicts a wicked, parasitic
and sycophantic character, whom he calls Placebo [2].
Much later, placebo came to mean a substance that can be
given to humour or gratify a patient rather than to exert a
genuine pharmacological effect.
The first recorded medical dictionary definition of
placebo refers to “a commonplace method or medicine”,
commonplace meaning common and pedestrian. Indeed,
in Motherby’s 1795 dictionary, placebo was defined as “a
commonplace method or medicine calculated to amuse
for a time, rather than for any other purpose” [3]. This
definition was maintained until 1937, when Taber’s
Digest of Medical Terms [4] defined placebo as an “inac-
tive substance” and a “substitute for medicine given to
deceive the patient”.
Although a placebo is still regarded as an “inactive”
substance, its impact can be profound. In clinical trials,
if its effects are not measured, the placebo response




There are at least four psychological mechanisms associ-
ated with the placebo response: (1) expectation, (2) condi-
tioning, (3) therapeutic relationship and (4) empowerment
[5]. Patients’ expectations are based on their cultural
background, on information given by the physician
(dosage schedule, careful explanation of advantages and
disadvantages) or written instructions, and on physical
aspects of the placebo (colour, shape, taste, formulation).
The old conditioning effect discovered by Pavlov is con-
nected with displaying of the treatment: if symptom relief
occurs following the administration of a particular tablet,
the relief will, over time, become conditioned to occur fol-
lowing use of that particular tablet. There is also consid-
erable evidence that a patient’s interpersonal relationships
play an important role. Social support influences a range
of physiological parameters (heart, glands, immune sys-
tem) and it provides a buffer against stress. Therefore, a
patient-centred physician–patient relationship (e.g., prop-
er interview conducted in a warm and friendly manner) is
likely to produce a better outcome than a formal consulta-
tion. Last but not least, the placebo response is associated
with empowerment, that is, the process of encouraging the
patient to take an active part in the decision-making
process regarding his treatment.
As all these factors can influence, to different extents
in different patients, the size, variability and duration of a
placebo response, this response becomes difficult to pre-
dict in advance.
Neurobiological mechanisms
Recently, there has been renewed scientific and public
interest in the placebo effect following the publication of
studies of its biological substrates. A placebo, through
raised expectations and/or conditioning, can reduce pain
by both opioid and non-opioid mechanisms. In the first
case, placebo analgesia is typically blocked by the opioid
antagonist naloxone, whereas in the second case it is not
[6]. Central respiratory structures in the brainstem may
also be inhibited by endogenous opioids as well as by
placebo. The beta-adrenergic sympathetic system of the
heart may also be inhibited during placebo analgesia,
although the underlying mechanism is not known (reduc-
tion of the pain itself and/or direct action of endogenous
opioids). Cholecystokinin [7] antagonises the effects of
endogenous opioids, thereby reducing the placebo
response. Placebo can also act on 5-HT-dependent hor-
mone secretion, at both pituitary and adrenal gland level,
thereby mimicking the effect of triptans.
There is evidence that the endogenous opioid system
is implicated in the mediation of placebo effects under
conditions of expectation of analgesia [8]. Using func-
tional magnetic resonance imaging to measure, indirect-
ly, neuronal activity during the administration of placebo
with expectation of analgesia, Wager et al. [9] showed a
significant effect on the activation of the µ-opioid system
(dorsolateral prefrontal cortex, rostral anterior cingulate,
left nucleus accumbens and right anterior insula). PET
studies have shown that in painful conditions placebo
will activate the same central structures of the pain
matrix as opioids [10].
Placebo and headache
According to the International Headache Society (IHS)
[11], controlled trials of acute migraine medication should
be carried out “in accordance with the principle of the
Declaration of Helsinki” [12]. Later on, however, the
same IHS guidelines explicitly recommend the use of
placebo in trials of abortive medications. Therefore, a
contradiction arises, as the declaration of Helsinki states
that when an effective treatment for a disease exists, it is
unethical to assign patients in a research study to a treat-
ment known to be less effective. But standards for the
acceptable use of placebo in clinical trials are changing. It
is now necessary to provide ethical and scientific justifi-
cation for the use of placebo in some therapeutic areas.
The use of placebo in trials of acute medication is gener-
ally regarded as justified in situations in which withhold-
ing the best current treatment will result in only temporary
discomfort and no serious adverse effects. In addition,
most protocols allow the use of rescue medication two
hours after intake of study medication.
Placebo and migraine
It is well known that the placebo response in clinical trials
of acute migraine treatments is widely variable, ranging
from 6% to 47% of patients. It has thus been recommend-
ed that active drugs for migraine must be shown to be sig-
nificantly superior to placebo [12].
Bendtsen et al. [13] evaluated the placebo response in
placebo-controlled randomised clinical trials of analgesics
in migraine attacks that fulfilled the IHS criteria. Eleven
studies were included in their review. A “headache
response” (i.e., defined as a proportion of attacks that
decreased in pain severity from moderate–severe to mild
or no headache within 2 h) was obtained after treatment
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with placebo in 30% (mean) of migraineurs, although the
range (variability) was large (7%–50%). Pain-free rates
two hours after treatment with placebo were lower (mean
9%, variability 7%–17%), suggesting that that this is a
more robust outcome measure.
Loder et al. [14] reviewed literature reports (1991–2002)
of placebo-controlled trials with triptans in acute migraine,
and found 31 trials that met their inclusion criteria. The
mean proportion of patients with a headache response to
placebo at 2 h was 28.5±8.7% (range 15%–50%), while the
mean proportion of patients with a pain-free response to
placebo at 2 h was 6.1±4.4% (range 5%–17%).
Placebo response in children and adolescents with
migraine presents a particular challenge, not least
because placebo rates are enhanced in this age group
[14]. Lewis et al. [15] reviewed the limited available
data on the use of analgesics and triptans in placebo-con-
trolled trials of migraine in children and adolescents and
found a large variability in the placebo response: present
in 37%–53% of patients treated with placebo analgesics/
non-steroidal anti-inflammatory drugs (NSAIDs), and in
28%–65% of those treated with placebo triptans. This
explains why most trials investigating the efficacy of
triptans in children and adolescents have failed to obtain
conclusive findings [16]. As the response rates to trip-
tans, however, were comparable with those found in
adults, the variability of the placebo response must be
taken into account, as must strategies to minimise it. One
possibility could be to treat consecutive attacks with a
placebo, which will likely show a decreasing response
over time [17].
The “nocebo effect”
Although placebo response is used as an efficacy out-
come, placebo is also associated with a spectrum of
adverse events, reported across placebo-controlled clini-
cal trials – the “nocebo” effect [18].
In a review of 109 double-blind, placebo-controlled
drug trials involving a total of 1228 healthy volunteers,
adverse effects were spontaneously reported by an aver-
age of 19% of those on placebo [19].
The following are examples of adverse effects that
have been reported in patients receiving placebo, in
placebo-controlled trials (any indication): drowsiness,
fatigue, unsteady gait, mental confusion, motor retarda-
tion, insomnia, nervousness, motor agitation, headache,
nausea, vomiting, constipation, diarrhoea, vertigo, dry
mouth, leucopenia and death. In view of this, there is
clearly a need to attempt to disentangle adverse effects
associated with placebo from those associated with
active medications, in order to arrive at a more accurate
profile of the tolerability and safety of the active med-
ication. In placebo-controlled trials of migraine, adverse
effects may occur with placebo in >30% of patients [19],
and in triptan trials the mean (±SD) proportion of
patients reporting an AE on placebo was 23.4±14.1%
(range 5%–74%) [20].
As placebo response rates in clinical trials in migraine
may vary with different study designs, primary outcome
measures and patient characteristics, and considering that
the magnitude of the placebo effect can be influenced by
a patient’s expectations (conditioning), the severity of the
pain at baseline and the rate of spontaneous resolution,
placebo-subtracted outcome data may provide a more
accurate profile of the active medication [13]. Adverse
events with placebo triptans in migraine tend to be lower
in European compared to North American studies [13],
while within Europe, placebo response rates are higher in
southern countries than in Scandinavia.
Even so, there are, inevitably, exceptional cases, as
shown by the interesting report by Pascual-Lozano et al.
[21], of a patient whose migraine, repeatedly refractory to
analgesics, NSAIDs, ergotamine and opioids, responded
well and consistently to placebo.
Potential lessons to be learned from placebo-controlled
trials in migraine
Placebo response rates vary in studies presenting differ-
ent designs, primary outcome measures and patient
characteristics [12, 13]. However, the magnitude of
these placebo effects in relation to active treatment does
not justify the rate of spontaneous resolution, patient
expectations (conditioning) and the severity of pain at
baseline [12]. Furthermore, the lack of difference
between a standard and a novel comparator does not
prove the efficacy of the latter in the absence of a place-
bo group [10–12]. In addition, adverse events can only
be appreciated when a placebo group is present. It has
been shown that even though active drugs may be effec-
tive, a high placebo response rate may confound the evi-
dence [18], and a high placebo response rate has been
found to correlate with a high response on the corre-
sponding active drug [12]. At the present time, compar-
ison of results across trials is dangerous [12]. Placebo-
subtracted data enable a more rigorous comparison
across different trials.
In summary, although medical ethics committees are
becoming increasingly resistant to the use of placebo in
acute migraine trials, placebo remains the pivotal com-
parator in trials of migraine medications.
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